Name: Name:Ly 334370
Brand: Angene
SKU: AG00AKRF
Rating: 90 (10 reviews)

Catalog Number:

AG00AKRF

Chemical Name:

Ly 334370

CAS Number:

182563-08-2

Molecular Formula:

C21H22FN3O

Molecular Weight:

351.4173

MDL Number:

MFCD19686973

IUPAC Name:

4-fluoro-N-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]benzamide

InChI:

InChI=1S/C21H22FN3O/c1-25-10-8-14(9-11-25)19-13-23-20-7-6-17(12-18(19)20)24-21(26)15-2-4-16(22)5-3-15/h2-7,12-14,23H,8-11H2,1H3,(H,24,26)

InChI Key:

MDMJLMDBRQXOOI-UHFFFAOYSA-N

SMILES:

CN1CCC(CC1)c1c[nH]c2c1cc(cc2)NC(=O)c1ccc(cc1)F

UNII:

5Q7I1WL2UY

Complexity:

486

Compound Is Canonicalized:

Yes

Covalently-Bonded Unit Count:

Defined Atom Stereocenter Count:

Defined Bond Stereocenter Count:

Exact Mass:

351.175g/mol

Formal Charge:

Heavy Atom Count:

Hydrogen Bond Acceptor Count:

Hydrogen Bond Donor Count:

Isotope Atom Count:

Molecular Weight:

351.425g/mol

Monoisotopic Mass:

351.175g/mol

Rotatable Bond Count:

Topological Polar Surface Area:

48.1A^2

Undefined Atom Stereocenter Count:

Undefined Bond Stereocenter Count:

XLogP3:

3.6

Title	Journal
5-Hydroxyptryptamine 1F (5-HT1F) receptor agonism. A possible new treatment principle for acute migraine attacks.	Cephalalgia : an international journal of headache 20101001
Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan.	Cephalalgia : an international journal of headache 20101001
Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan--a randomised proof-of-concept trial.	Cephalalgia : an international journal of headache 20101001
5-HT(1F) Receptor agonists: a new treatment option for migraine attacks?	Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 20100401
Designing selective, high affinity ligands of 5-HT1D receptor by covalent dimerization of 5-HT1F ligands derived from 4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]benzamide.	Journal of medicinal chemistry 20080626
[3H]LY334370, a novel radioligand for the 5-HT1F receptor. I. In vitro characterization of binding properties.	Naunyn-Schmiedeberg's archives of pharmacology 20050301
[3H]LY334370, a novel radioligand for the 5-HT1F receptor. II. Autoradiographic localization in rat, guinea pig, monkey and human brain.	Naunyn-Schmiedeberg's archives of pharmacology 20050301
Design, synthesis and evaluation of bicyclic benzamides as novel 5-HT1F receptor agonists.	Bioorganic & medicinal chemistry letters 20041220
Substituted furo[3,2-b]pyridines: novel bioisosteres of 5-HT 1F receptor agonists.	Bioorganic & medicinal chemistry letters 20040105
Novel potent 5-HT(1F) receptor agonists: structure-activity studies of a series of substituted N-[3-(1-methyl-4-piperidinyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]amides.	Journal of medicinal chemistry 20030703
Crystal forms of LY334370 HCl: isolation, solid-state characterization, and physicochemical properties.	Journal of pharmaceutical sciences 20030601
Treatment of acute migraine.	Lancet (London, England) 20020302
Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial.	Lancet (London, England) 20011013
The anti-migraine 5-HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs.	British journal of pharmacology 20010801